Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases

被引:0
作者
Naeemeh Khalesi
Shahla Korani
Mitra Korani
Thomas P. Johnston
Amirhossein Sahebkar
机构
[1] Shahid Beheshti University of Medical Science,Biotechnology Department, School of Advanced Technologies in Medicine
[2] Kermanshah University of Medical Sciences,Research Center of Oils and Fats
[3] Buali (Avicenna) Research Center,Nanotechnology Research Center
[4] Mashhad University of Medical Science,Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy
[5] University of Missouri-Kansas City,Applied Biomedical Research Center
[6] Mashhad University of Medical Sciences,Biotechnology Research Center, Pharmaceutical Technology Institute
[7] Mashhad University of Medical Sciences,School of Medcine
[8] The University of Western Australia,School of Pharmacy
[9] Mashhad University of Medical Sciences,undefined
来源
Inflammopharmacology | 2021年 / 29卷
关键词
Autoimmune disease; Bortezomib; Proteasome inhibitor; Proteasome; NF-kB; ER homeostasis;
D O I
暂无
中图分类号
学科分类号
摘要
Autoimmune diseases (ADs) are conditions in which the immune system cannot distinguish self from non-self and, as a result, tissue injury occurs primarily due to the action of various inflammatory mediators. Different immunosuppressive agents are used for the treatment of patients with ADs, but some clinical cases develop resistance to currently available therapies. The proteasome inhibitor bortezomib (BTZ) is an approved agent for first-line therapy of people with multiple myeloma. BTZ has been shown to improve the symptoms of different ADs in animal models and ameliorated symptoms in patients with systemic lupus erythematous, rheumatoid arthritis, myasthenia gravis, neuromyelitis optica spectrum disorder, Chronic inflammatory demyelinating polyneuropathy, and autoimmune hematologic diseases that were nonresponsive to conventional therapies. Proteasome inhibition provides a potent strategy for treating ADs. BTZ represents a proteasome inhibitor that can potentially be used to treat AD patients resistant to conventional therapies.
引用
收藏
页码:1291 / 1306
页数:15
相关论文
共 50 条
[41]   The Ubiquitin-Proteasome System and Its Role in Inflammatory and Autoimmune Diseases [J].
Michael A.Maldonado .
Cellular&MolecularImmunology, 2006, (04) :255-261
[42]   The Ubiquitin-Proteasome System and Its Role in Inflammatory and Autoimmune Diseases [J].
Wang, Jingsong ;
Maldonado, Michael A. .
CELLULAR & MOLECULAR IMMUNOLOGY, 2006, 3 (04) :255-261
[43]   Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis [J].
Li, Shi-Jun ;
Hao, Jian ;
Mao, Yu ;
Si, Yu-Ling .
TURKISH JOURNAL OF HEMATOLOGY, 2020, 37 (01) :13-19
[44]   The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes [J].
Mondanelli, Giada ;
Albini, Elisa ;
Pallotta, Maria T. ;
Volpi, Claudia ;
Chatenoud, Lucienne ;
Kuhn, Chantal ;
Fallarino, Francesca ;
Matino, Davide ;
Belladonna, Maria L. ;
Bianchi, Roberta ;
Vacca, Carmine ;
Bicciato, Silvio ;
Boon, Louis ;
Ricci, Giovanni ;
Grohmann, Ursula ;
Puccetti, Paolo ;
Orabona, Ciriana .
FRONTIERS IN IMMUNOLOGY, 2017, 8
[45]   Ixazomib: an oral proteasome inhibitor for the treatment of multiplemyeloma [J].
Shah, Neil ;
Biran, Noa ;
Vesole, David H. .
EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (01) :105-113
[46]   Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519 [J].
Vanderlugt, CL ;
Rahbe, SM ;
Elliott, PJ ;
Dal Canto, MC ;
Miller, SD .
JOURNAL OF AUTOIMMUNITY, 2000, 14 (03) :205-211
[47]   Linking the activity of bortezomib in multiple myeloma and autoimmune diseases [J].
Skrott, Zdenek ;
Cvek, Boris .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 92 (02) :61-70
[48]   Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells [J].
Kitagaki, J. ;
Miyauchi, S. ;
Xie, C. J. ;
Yamashita, M. ;
Yamada, S. ;
Kitamura, M. ;
Murakami, S. .
JOURNAL OF PERIODONTAL RESEARCH, 2015, 50 (02) :248-255
[49]   Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines [J].
Miyamoto, Yuichiro ;
Nakagawa, Shunsuke ;
Wada-Hiraike, Osamu ;
Seiki, Takayuki ;
Tanikawa, Michihiro ;
Hiraike, Haruko ;
Sone, Kenbun ;
Nagasaka, Kazunori ;
Oda, Katsutoshi ;
Kawana, Kei ;
Nakagawa, Keiichi ;
Fujii, Tomoyuki ;
Yano, Tetsu ;
Kozuma, Shiro ;
Taketani, Yuji .
ONCOLOGY REPORTS, 2013, 29 (01) :51-57
[50]   The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan [J].
Sanchez, Eric ;
Li, Mingjie ;
Steinberg, Jeffrey A. ;
Wang, Cathy ;
Shen, Jing ;
Bonavida, Benjamin ;
Li, Zhi-Wei ;
Chen, Haiming ;
Berenson, James R. .
BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (04) :569-581